Henry Ginsberg

Henry is a Professor of Medicine at Columbia University and has been so for the last 35 years, and a past Director for the Irving Institute for Clinical & Translational Research. Henry is an active senior investigator of cardiovascular disease and lipoprotein metabolism research with detailed knowledge about Lp(a) (the target for the pipeline project SLN360) but also all the drug development in the cardiovascular disease and lipoprotein metabolism field that has preceded it - the successes and the failures in a complicated area of disease. Henry has over 300 peer-reviewed and invited publications and serves as the Chief Medical Officer for the Lp(a) Foundation, a key partner in the development of drugs targeting Lp(a).